Improving diagnosis and treatment for advanced ovarian cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to address chemotherapy resistance in high-grade serous ovarian cancer (HGSOC) by developing personalized treatment regimens for patients who are likely to respond poorly to standard therapies. It involves recruiting newly diagnosed advanced stage HGSOC patients and utilizing advanced techniques such as whole genome sequencing, RNA sequencing, and circulating tumor DNA analysis. The study will also integrate digital pathology and clinical data with AI methods to identify mechanisms of resistance and suggest targeted therapies. The ultimate goal is to enhance clinical decision-making and improve patient outcomes through personalized medicine approaches.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with a suspected ovarian cancer diagnosis treated at the Turku University Hospital
* Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

* Age \<18 years, too poor condition for active treatment (surgery, chemotherapy)
* FDG PET/CT scan is not performed for patients with diabetes mellitus and poor glucose balance.

Where it's running

• Turku University Hospital
  Turku, Finland Recruiting

Study contacts

• Principal investigator: Johanna Hynninen, MD, PhD — Turku University Hospital
• Study coordinator: Johanna Hynninen
• Email: johanna.hynninen@utu.fi
• Phone: +358 50 5383554

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Testing ZM008 alone and with Pembrolizumab in patients with advanced solid tumors

  This study is testing a new treatment called ZM008, alone and with another drug called Pembrolizumab, to see if it can help patients with advanced solid tumors who have run out of other treatment options.

  Recruiting at 3 sites Phase 1 Zumutor Biologics Inc. · Boston, Massachusetts and 2 other locations · NCT06451497

• Testing a new dosing method of niraparib for ovarian cancer treatment

  This study is testing a new way to give niraparib to see if it helps people with newly diagnosed advanced ovarian cancer stay healthy longer after their initial chemotherapy.

  Recruiting Phase 2 Sunnybrook Health Sciences Centre · Toronto, Ontario · NCT05961124

• Modi-1 vaccine for advanced cancers

  This study is testing a new vaccine for people with advanced cancers like triple negative breast cancer and ovarian cancer to see if it can boost their immune response and work better with other treatments.

  Recruiting at 13 sites Phase 1/2 Scancell Ltd · Brighton, Default and 15 other locations · NCT05329532

• Adaptive chemotherapy approach for relapsed ovarian cancer

  This study is testing if adjusting the dose of carboplatin based on a blood marker can help women with relapsed ovarian cancer feel better and have fewer side effects from treatment.

  Recruiting Phase 2 University College, London · London · NCT05080556

• Using a uterine wash and a blood protein test to find ovarian cancer early

  This project will try to find tumor DNA in a uterine wash plus protein markers in blood to detect ovarian or fallopian tube cancer in women having surgery for a suspected ovarian growth or BRCA1/2 carriers having risk-reducing surgery.

  Recruiting at 5 sites Massachusetts General Hospital · Little Rock, Arkansas and 5 other locations · NCT04794322

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.